Top 10 Selling Cancer Drugs of 2025: Global Sales Rankings & Revenue Data

Rank	Brand	Company	Indications	Revenues $ billion
1	Keytruda	Merck	Melanoma, NSCLC, HNSCC, Hodgkin Lymphoma, Urothelial Cancer, RCC, HCC and several other cancers	$31.7
2	Darzalex	Johnson and Johnson		$14.5
3	Opdivo	Bristol Myers Squibb		$10.0
4	Tagrisso	AstraZeneca		$7.2
5	Imfinzi	AstraZeneca		$6.0
6	Verzenio	Eli Lilly		$5.7
7	Kisqali	Novartis		$4.8
8	Tecentriq	Roche		$4.6
9	Ibrance	Pfizer		$4.1
10	Perjeta	Roche		$3.8

Keytruda

Merck’s mega-blockbuster immunotherapy pembrolizumab (Keytruda) firmly held its crown as the world's top-selling prescription drug in 2025. Generating an estimated $31.7 billion in global sales, the anti-PD-1 checkpoint inhibitor logged roughly 7% year-over-year growth, accounting for a massive share of Merck's overall pharmaceutical revenue.

Why It Dominates the Market

Keytruda's commercial dominance is driven by an unprecedented regulatory footprint that spans more than 20 indications across both solid tumors and hematological malignancies, including advanced melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma.

Rather than relying purely on late-stage, metastatic treatment cycles, Merck has aggressively pushed Keytruda into earlier lines of defense. The drug's target patient pool expanded significantly due to rapid adoption in perioperative (neoadjuvant and adjuvant) settings, where it is administered both as a standalone monotherapy and in synergy with standard chemoradiotherapy.

While Keytruda remains unmatched at the top of the oncology market, all eyes are on Merck’s pipeline strategies as the industry prepares for the drug's looming 2028 patent expiration.